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Thrombin is a potent activator of human glomerular epithelial cells (HGEC). Here we compare short-term and long-term effects of thrombin and 
thrombin receptor agonist peptide (TRAP) which selectively activates the functional thrombin receptor. TRAP, as thrombin, increases intracellular 
free Ca 2÷ concentration and acts synergistically with growth factors possessing tyrosine kinase receptors on DNA synthesis. Thrombin induces 
synthesis of proteins of the fibrinolytic system and cell proliferation if it is present for at least 8 h. TRAP alone does not stimulate protein synthesis 
and is not mitogenic. However, in the presence of the aminopeptidase inhibitor amastatin all long-term effects of thrombin can be fully mimicked 
by TRAR In conclusion, different effects of thrombin and TRAP may be related to the degradation ofTRAP by cellular ectoenzymes. The recently 
cloned thrombin receptor accounts for early intracellular signals and long-term cellular effects that require sustained activation of this receptor. 
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1. INTRODUCTION 
Human extracapillary glomerulonephritis is charac- 
terized by glomerular fibrin deposition and prolifera- 
t?on of HGEC, possibly mediated by thrombin [1]. In 
addition to its critical role in thrombosis and haemosta- 
sis, thrombin exhibits multiple cell-activating functions 
[2,3]. Thrombin is a potent platelet agonist [4], chemo- 
tactic for monocytes [5], mitogenic for mesenchymal 
cells [6] and activates endothelial cells [7]. The effects of 
thrombin on HGEC and signal transduction mecha- 
nisms involved have previously been described [8,9]. 
Recently, a functional receptor of thrombin has been 
cloned [10,11]. The thrombin receptor is a member of 
the multigene family of seven transmembrane domain 
receptors, couples to Gq-like and Gi-like guanine nucle- 
otide-binding proteins (G-proteins) and stimulates 
phosphoinositide hydrolysis and inhibition of adenylate 
cyclase [12,13]. 
Receptor activation occurs by cleavage of the N-ter- 
minal extracellular domain of the receptor by thrombin. 
The new N-terminus exposed acts as a tethered peptide 
ligand and activates the receptor [10,11]. Accordingly, 
receptor activation can be mimicked by synthetic pep- 
tides corresponding to the new N-terminus (i.e. 
SFLLRNP = TRAP) [14]. 
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Abbrevations: HGEC, human glomerular epithelial cells; TRAP, 
thrombin receptor agonist peptide; u-PA, urokinase-type lasminogen 
activator; t-PA, tissue-type plasminogen activator; PAI-I, plasmino- 
gen activator inhibitor type I ; EGF, epidermal growth factor; bFGF, 
basic fibroblast growth factor. 
Whether the cloned functional thrombin receptor is 
responsible for all cellular effects of thrombin remains 
controversial. In contrast to thrombin, TRAP does not 
mediate the second phase of p44 mitogen-activated pro- 
tein kinase activation and DNA synthesis reinitiation i  
CCL39 fibroblasts, whereas it is as competent as throm- 
bin in activating phospholipase C and in inhibiting 
adenylate cyclase [15,16]. In endothelial cells, TRAP 
induces an increase in intracellular f ee Ca 2+ concentra- 
tion and expression of P-selectin, but not expression of 
intracellular adhesion molecule 1, increase in transen- 
dothelial permeability and translocation of protein ki- 
nase C that are stimulated by thrombin [17,18]. 
Recently, Coller et al. have demonstrated that amin- 
opeptidase M in plasma nd on endothelial cells cleaves 
and thereby inactivates TRAP [19]. Accordingly, inhibi- 
tion of aminopeptidase M enhances platelet aggregation 
induced by TRAP pointing to the possibility of rapid 
degradation of TRAP in in vivo and in vitro systems. 
Here we compare the cellular effects of thrombin and 
TRAP to determine the role of the functional thrombin 
receptor in HGEC. 
2. MATERIALS AND METHODS 
2.1. Materials 
The following materials have been obtained as indicated: purified 
human ~-thrombin (3000 U/mg, 1 U/ml = t0 -8 M), collagenase type 
IV, hirudin, amastatin, bestatin, thiorphan from Sigma; polyclonal 
antibodies to human tissue-type plasminogen activator (t-PA) and to 
human urokinase-type lasminogen activator (u-PA), polyclonal and 
monoclonal (MAI 12) antibodies to plasminogen activator inhibitor 
1 (PAI-1) from Biopool; ionomycin, fura-2 aeetoxymethylester from 
Calbiochem; epidermal growth factor (EGF) and [3H]thymidine (20 
Ci/mmol) from Amersham; basic fibroblast growth factor (bFGF) 
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from Choay, Paris. TRAP (SFLLRNP) was a generous gift from Dr. 
Seller, Bristol-Squibb, Princeton. 
2.2. Ceil culture 
Glomerular epithelial cells were obtained by collagenase digestion 
of isolated glomeruli derived from normal human kidneys judged to 
be unsuitable for transplantation. They were purified using cloning 
rings and identified by their morphologic and functional features as 
previously described [20]. 
Incubations were performed on the third subculture of HGEC 
grown in multidish wells (Nunclon, Nunc) in normally defined me- 
dium as described [8]. Before reaching confluence, cells were washed, 
growth arrested by serum starvation for 24 h and incubated with the 
compound to be tested for 24 h. Culture media were collected for 
determination of fibrinolytic omponents. 
2.3. Measurement of DNA synthesis 
Six hours before the end of incubation, 1 ,uCi [3H]thymidine was 
added to each well. Cells were washed, incubated 30 rain in minimum 
defined medium containing 1rag/rot non-labeled thymidine and then 
harvested by trypsinization. Cells were filtered on 0.45 pm Millipore 
filter and the radioactivity of the filter was counted in a ]/-scintillation 
counter. 
2.4. Determination of o, tosolic Jree calcium concentration [Cd+]~ 
[Ca2+]i in HGEC was measured using fura-2 acetoxymethylester (4 
pM) exactly as described [9]. Fluorescence was monitored continu- 
ously in a Perkin-Elmer model LS-5 spectrofluorometer using 339 nm 
excitation/500 nm emission wavelengths. Calibration of the Ca2÷-de - 
pendent fluorescence was obtained by addition of 20/~M ionomycin 
(maximum fluorescence, Fro,x) followed by 4 mM EGTA in 60 mM 
Tris-HCl buffer, pH 10.5 (minimal fluorescence, Fmi,, ). [Ca2+]~ was 
calculated using the following formule: 
[Ca2+]i = (F -  Fmi . x Kd/(Fma x - F) with K~ = 224 nM. 
2.5. Enzyme linked immunosorbent assay for t-PA, u-PA and PAl-1 
Determination of u-PA, t-PA and PAI-1 antigen were performed as 
previously described [8]. The detection limits for PAI-1, u-PA, and 
t-PA were 0.4 ng/ml, 0.9 ng/ml, and 0.14 ng/ml, respectively. 
3. RESULTS 
3.1. Effect of thrombin and TRAP on early transmem- 
brane signals 
As shown in Fig. 1, thrombin and TRAP induce a 
rapid and transient increase in intracellular free Ca 2+ 
concentration which was dose-dependent. Maximal re- 
sponses by saturing concentrations of TRAP (100 #M) 
and thrombin (80 nM) are similar. The aminopeptidase 
inhibitor amastatin has no effect on thrombin and 
TRAP induced Ca 2+ dependent fluorescence (not 
shown). 
In parallel, TRAP is as potent as thrombin in stimu- 
lating GTPase activity and generation of inositol- 
trisphosphate (manuscript in preparation). 
3.2. Long-term effects of thrombin and TRAP 
It has previously been shown that thrombin is mito- 
genie for HGEC [8]. Thrombin induces a dose-depend- 
ent increase in DNA synthesis in HGEC (Fig. 2A). The 
continuous presence of thrombin for at least 8 h is re- 
quired to induce cell-cycle re-entry. TRAP alone has no 
mitogenic effect (Fig. 2B). However, in the presence of 
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Fig. 1. Increase in intracellular free Ca z+ concentration. Dose-re- 
sponse effect of thrombin (©) and TRAP (It) on fura-2 fluorescence. 
Means of 5 experiments are presented. 
the aminopeptidase inhibitor amastatin, TRAP is also 
able to stimulate DNA synthesis. Amastatin is the most 
effective inhibitor tested so far. Another aminopepti- 
dase inhibitor, bestatin (up to 100/tM) is only partially 
effective in protecting TRAP from degradation. Thior- 
phan (up to t 00 ~M), an inhibitor of neutral endopepti- 
dase [21], has no effect. In contrast, amastatin does not 
influence thrombin induced mitogenesis (Fig. 2A). 
HGEC in culture synthesize u-PA, t-PA and PAI-1. 
It has previously been shown [8] that thrombin induces 
a 2-3-fold increase in u-PA, t-PA and PAI-1 antigen 
release in the supernatant during 24 h (Fig. 3). TRAP 
alone has no effect. In the presence of amastatin, how- 
ever, TRAP is as potent as thrombin in inducing protein 
synthesis (Fig. 3). 
The relative potencies of TRAP and thrombin were 
similar for long- and short-term effects. The higher po- 
tency of thrombin compared to TRAP is consistent with 
the proposed model of receptor activation in which 
thrombin acts enzymatically whereas TRAP acts by 
binding. 
3.3. Synergisrn between thrombin and growth factors" 
possessing tyrosine kinase receptors 
Growth factors, activating receptor associated G- 
proteins or receptor tyrosine kinases can act synergisti- 
cally on DNA synthesis by stimulation of different in- 
tracellular pathways [22]. For example, thrombin po- 
tentiates DNA synthesis in cooperation with EGF and 
bFGF [15,23], platelet-derived growth factor and insu- 
lin [24]. 
Thrombin-induced mitogenesis totally blocked by 
addition ofhirudin, a potent inhibitor of thrombin [25], 
one hour after thrombin. However, a synergistic effect 
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with EGF and bFGF is still observed (Table I). This 
suggests that a transient phase of activation induced by 
thrombin during one hour is sufficient for a synergistic 
action with other growth factors, but not enough to 
induce mitogenesis by itself. Accordingly, a synergistic 
effect with EGF and bFGF can also be mimicked by 
TRAP in the absence of  aminopeptidase inhibitors 
(Table I ) .  
4. D ISCUSSION 
Both thrombin and TRAP induce G-protein-coupled 
early intracellular signals, Here the increase in intracel- 
lular free Ca 2+ concentration is shown as an example. 
In contrast, TRAP can mimick long-term effects of 
thrombin as induction of cell proliferation and protein 
synthesis only in the presence of  aminopeptidase inhib- 
itors. 
HGEC are rich in cell surface associated proteolytic 
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Fig. 3. Effect of thrombin and TRAP on the synthesis of fibrinolytic 
components. Thrombin (20 nM) or TRAP (50 pM) were incubated in 
the presence or absence of amastatin (10 ~tM) and the concentration 
of u-PA, t-PA and PAI-1 antigen in the conditioned media were 
measured. Means _+ S.E.M. of four different experiments made in 
triplicate are presented. 
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Fig. 2. Stimulation of DNA synthesis. Dose-response ffects of 
thrombin (A) and TRAP (B) on [~H]thymidine incorporation in the 
presence (e) or absence (o) of amastatin (10 pM). Means of 3 exper- 
iments made in triplicate are presented. 
enzymes. Ectoenzymes like aminopeptidase-A, amino- 
peptidase-N and neutral endopeptidase are present 
and responzible for proteolytic activation/inactivation 
of  bioactive peptides [26]. Aminopeptidase-N-like activ- 
ity on HGEC has been detected and could be inhibited 
by amastatin [27] suggesting rapid degradation of 
TRAP by aminopeptidase-N, 
Degradation of  TRAP may be one explanation for 
the lack of medium- and long-term effects of TRAP in 
some cell systems and may depend finally on the cellular 
equipment with proteolytic enzymes. The sustained ac- 
tivation of  the functional thrombin receptor is required 
to observe long-term cellular effects. This is indicated 
by the lack of  effect of  TRAP alone, which is rapidly 
degraded, on protein synthesis and cell proliferation 
and by the inhibition of thrombin effects when hirudin 
is added up to 8 h after thrombin. 
In contrast, aminopeptidase inhibitors do not influ- 
ence thrombin-induced cellular effects. Theretbre the 
aminopeptidase degrading TRAP does not appear to 
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Table I 
Effect of growth factors, thrombin and TRAP on [3H]thymidine incor- 
poration in HGEC 
Culture treatment [3H]Thymidine incorporation (cpm/5 x 10 a cells) 
+ EGF + bFGF 
(10 ng/ml) (50 ng/ml) 
Basal 461 + 55 1282 + 146 877_+ 51 
Thrombin (20 nM) 1489 + 201 2995 + 264 2267 + 163 
Thrombin (20 nM) 
+ hirudin (2/~M)* 451 + 60 2141 _+ 315 1443 + 145 
TRAP (50 yM) 493 + 46 2105 _+ 234 1367 + 114 
Means + S.E.M. of 4 different experiments made in triplicate are 
presented. 
*Hirudin was added one hour after thrombin. 
inact ivate the tethered l igand produced  by thrombin  
c leavage o f  its receptor  under  the exper imenta l  condi -  
t ions used. This is in good  agreement  with results o f  
Col ler  et al. [19] on platelet aggregat ion.  
In  conclus ion,  our  results suggest that  the recently 
c loned funct ional  th rombin  receptor  mediates  early in- 
tracel lu lar  signals and long- term effects o f  th rombin  on 
HGEC.  Induct ion  o f  long- term effects requires sus- 
ta ined act ivat ion o f  this receptor  by thrombin .  
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